FMR LLC & Abigail Johnson Maintain 14.6% Stake in Zentalis Pharma
Ticker: ZNTL · Form: SC 13G/A · Filed: Feb 9, 2024 · CIK: 1725160
Complexity: simple
Sentiment: bullish
Topics: institutional-ownership, amendment, pharmaceuticals, insider-holding
TL;DR
**FMR LLC and Abigail Johnson still own 14.6% of Zentalis Pharma, a big vote of confidence!**
AI Summary
FMR LLC, a major investment firm, and its principal owner, Abigail P. Johnson, have filed an amendment to their SC 13G, indicating they collectively beneficially own 10,336,971 shares of Zentalis Pharmaceuticals Inc. common stock, representing 14.607% of the company. This filing, dated February 9, 2024, shows a significant, continued stake in Zentalis, signaling FMR's ongoing confidence in the pharmaceutical company. For investors, this means a large institutional holder maintains a substantial position, which can be seen as a vote of confidence in Zentalis's future prospects.
Why It Matters
This filing shows that a major institutional investor, FMR LLC, and its leader, Abigail P. Johnson, continue to hold a significant portion of Zentalis Pharmaceuticals, which can influence stock stability and investor sentiment.
Risk Assessment
Risk Level: low — The filing indicates a stable, significant institutional ownership, which generally reduces volatility risk for the stock.
Analyst Insight
Investors should note the continued strong institutional backing from FMR LLC, which could signal long-term confidence in Zentalis Pharmaceuticals. This stability might reduce short-term volatility and could be a positive indicator for potential investors.
Key Numbers
- 10,336,971 — Shares Beneficially Owned (Represents the total common stock shares of Zentalis Pharmaceuticals Inc. held by FMR LLC and Abigail P. Johnson.)
- 14.607% — Percent of Class (Indicates the significant ownership stake FMR LLC and Abigail P. Johnson have in Zentalis Pharmaceuticals Inc.)
Key Players & Entities
- FMR LLC (company) — reporting person and parent holding company
- Abigail P. Johnson (person) — reporting person, principal owner of FMR LLC
- Zentalis Pharmaceuticals, Inc. (company) — subject company, issuer of the common stock
- 10,336,971 (dollar_amount) — total shares beneficially owned by FMR LLC and Abigail P. Johnson
- 14.607% (dollar_amount) — percentage of Zentalis Pharmaceuticals Inc. common stock beneficially owned
Forward-Looking Statements
- FMR LLC will maintain a significant ownership stake in Zentalis Pharmaceuticals Inc. for the foreseeable future. (FMR LLC) — high confidence, target: 2025-02-09
FAQ
Who are the primary reporting persons in this SC 13G/A filing for Zentalis Pharmaceuticals Inc.?
The primary reporting persons are FMR LLC and Abigail P. Johnson, as stated in Item 1 of the filing.
What is the total number of Zentalis Pharmaceuticals Inc. common stock shares beneficially owned by the reporting persons?
FMR LLC and Abigail P. Johnson collectively beneficially own 10,336,971 shares of Zentalis Pharmaceuticals Inc. common stock, as detailed in Item 7 for both reporting persons and Item 4(a) for FMR LLC.
What percentage of Zentalis Pharmaceuticals Inc.'s common stock do the reporting persons beneficially own?
The reporting persons, FMR LLC and Abigail P. Johnson, beneficially own 14.607% of Zentalis Pharmaceuticals Inc.'s common stock, as indicated in Item 11 for both reporting persons and Item 4(b) for FMR LLC.
Under which rule is this Schedule 13G filed?
This Schedule 13G is filed pursuant to Rule 13d-1(b), as checked in the appropriate box at the beginning of the filing and stated in Item 3.
What is the CUSIP number for Zentalis Pharmaceuticals Inc. common stock?
The CUSIP number for Zentalis Pharmaceuticals Inc. common stock is 98943L107, as listed multiple times in the filing, including under Item 2(e).
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on February 9, 2024 by Abigail P. Johnson regarding Zentalis Pharmaceuticals, Inc. (ZNTL).